Sagent recalls more of its antibiotics manufactured in India

India flag

Sagent Pharmaceuticals ($SGNT) is widening its recall of antibiotics manufactured by one of its India-based contractors after a customer complained that small, dark particulate matter were found in the solution after it was reconstituted.

The latest action falls on the heels of a recall that came earlier this summer of 3,990 vials of oxacillin for injection. The Schaumburg, IL-based drug company, which specializes in sterile injectables, had another antibiotic-related recall earlier this year that involved a lot of an antifungus treatment that it said might be contaminated with an antibiotic. 

According to the most recent FDA Enforcement Report, Sagent announced a nationwide recall of one lot of oxacillin for injection manufactured by India-based Astral SteriTech. The foreign matter found in the vials was identified as iron oxide.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The company said in a release that it was unaware of any problems that might have resulted from patients using oxacillin from the recalled lot.

Although Sagent is on the cusp of becoming part of a Japanese company, for the time being it remains responsible for any recalls. Last month, Nichi-Iko said it would spend $736 million to buy Sagent in a deal it expects to close by the end of September.

- here’s the FDA notification

Read more:
Sagent recalls antibiotic after customers complain of particulates 
Japanese drugmaker buying Sagent to get U.S. beachhead
Sagent recalls fluconazole contaminated with antibiotic

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.